✦ LIBER ✦

Molecular markers in gliomas: impact for the clinician

✍ Scribed by Silvia Hofer; Andrew B. Lassman

Book ID: 107384395
Publisher: Springer-Verlag
Year: 2010
Tongue: English
Weight: 192 KB
Volume: 5
Category: Article
ISSN: 1776-2596
DOI: 10.1007/s11523-010-0157-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Molecular Genetics for the Clinician

✍ Cahn, AP 📂 Article 📅 1993 🏛 Nature Publishing Group 🌐 English ⚖ 263 KB

Unraveling molecular markers of biologic

Unraveling molecular markers of biologic therapies in glioma

✍ Andrew B. Lassman; Lauren E. Abrey 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 65 KB

Impact of molecular medicine on neuropsy

Impact of molecular medicine on neuropsychiatry: The clinician’s perspective

✍ J. Michael Ryan; Rebekah Loy; Pierre N. Tariot 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 251 KB

Prognostic molecular markers with no imp

Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study

✍ Wager, M; Menei, P; Guilhot, J; Levillain, P; Michalak, S; Bataille, B; Blanc, J 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 255 KB

Loss of heterozygosity for distal marker

Loss of heterozygosity for distal markers on 22q in human gliomas

✍ Juan A. Rey; M. Josefa Bello; Ana M. Jimenez-lara; Jesus Vaquero; M. Elena Kusak 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 French ⚖ 747 KB

Loss of constitutional heterozygosity as determined through the analysis of restriction-fragment-length polymorphism (RFLP) on tumoral and constitutional DNA has proven to be helpful to delimit the location of tumor-suppressor genes in the human genome. In malignant gliomas this approach indicates t

Clinical impact of genetic and molecular

Clinical impact of genetic and molecular markers in myelodysplastic syndromes (MDS)

✍ Peter Valent 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 100 KB